Optinate Combi (Risedronate 35 mg + Calcium 1000 mg)

What Is Optinate Combi and What Is It Used For?

Optinate Combi is a co-packaged therapeutic regimen rather than a single chemical entity. It was developed to address one of the most persistent problems in long-term osteoporosis management: non-adherence to combined antiresorptive and calcium therapy. In observational studies, fewer than half of patients prescribed an oral bisphosphonate for osteoporosis continue treatment at one year, and calcium co-medication compliance is similarly poor. By supplying both components in a single weekly pack with a built-in dosing calendar, Optinate Combi provides a practical, visually clear framework that helps patients stay on track.

The pharmacological rationale for the combination is straightforward. Risedronate sodium is a pyridinyl nitrogen-containing bisphosphonate that binds tightly to hydroxyapatite in bone and inhibits osteoclast-mediated resorption. It does this by interfering with the mevalonate pathway in osteoclasts, specifically by inhibiting farnesyl pyrophosphate synthase, leading to reduced osteoclast activity and survival. The net effect is a slowing of bone turnover, a gradual increase in bone mineral density (BMD), and improved bone microarchitecture. However, for new bone mineralisation to occur safely and effectively, an adequate supply of calcium and vitamin D must be available. This is where the calcium carbonate component fits in: each sachet provides 1000 mg of elemental calcium (typically equivalent to 2500 mg calcium carbonate) that supports ongoing bone mineralisation and protects against the mild transient reductions in serum calcium that can occur when bone turnover is suppressed.

Osteoporosis is a systemic skeletal disease characterised by low bone mass, disrupted bone microarchitecture, and increased fragility. The World Health Organization estimates that osteoporosis affects around 200 million people worldwide, with approximately one in three women and one in five men over 50 sustaining an osteoporotic fracture in their lifetime. The consequences are substantial: hip fractures are associated with a 20–25% increase in mortality in the year following fracture, a high rate of permanent loss of independence, and major costs to healthcare systems. Vertebral fractures, while often clinically silent, are strongly predictive of future fracture risk and are linked to chronic pain, height loss, kyphosis, and reduced quality of life.

Optinate Combi is specifically indicated for:

• Treatment of postmenopausal osteoporosis in women at increased risk of vertebral and non-vertebral fractures, including those with established (severe) disease.
• Reduction of fracture risk in patients with documented osteoporosis, typically defined by a BMD T-score of ≤ −2.5 at the spine or hip, or by the presence of a fragility fracture.
• Combined bisphosphonate and calcium supplementation in patients whose dietary calcium intake is inadequate, which is common in older adults.

The evidence base for risedronate in osteoporosis is extensive. The pivotal VERT (Vertebral Efficacy with Risedronate Therapy) trials, published in 1999 and 2000, showed that daily risedronate 5 mg reduced new vertebral fractures by approximately 41–49% and non-vertebral fractures by approximately 33–39% over three years. The landmark HIP study demonstrated a roughly 30% reduction in hip fractures in high-risk elderly women. Pharmacokinetic and bridging studies established therapeutic equivalence between the original daily 5 mg regimen and weekly 35 mg dosing, which is now the standard convenience-based regimen. Cochrane systematic reviews have consistently confirmed these benefits, and the drug is included in WHO and NICE osteoporosis guidelines.

The calcium component of Optinate Combi is supported by a long-established body of evidence showing that adequate calcium intake (typically 1000–1200 mg per day, combined with sufficient vitamin D) is a prerequisite for optimal response to bisphosphonate therapy and for safe prevention of treatment-emergent hypocalcaemia. Meta-analyses of calcium and vitamin D supplementation in patients on bisphosphonates have shown small but measurable additional benefits on BMD, particularly in older women with dietary calcium intakes below recommended targets.

What Should You Know Before Taking Optinate Combi?

Before starting Optinate Combi, your doctor will assess your overall bone health, fracture risk, kidney function, and calcium status. This usually includes a DXA scan to measure bone mineral density, a clinical fracture risk assessment (for example using the FRAX tool), and basic blood tests such as serum calcium, 25-hydroxyvitamin D, creatinine, and alkaline phosphatase. Correcting vitamin D deficiency and ensuring normal calcium levels before starting bisphosphonate therapy makes treatment both safer and more effective.

Contraindications

Optinate Combi must not be used in the following situations:

• Known hypersensitivity to risedronate sodium, calcium carbonate, or any other excipient in the tablet or sachet.
• Hypocalcaemia — low blood calcium. This must be corrected before starting bisphosphonate therapy, because further suppression of bone turnover can trigger symptomatic hypocalcaemia.
• Hypercalcaemia or hypercalciuria — elevated calcium in the blood or urine. The daily calcium component of Optinate Combi would worsen the condition.
• Severe renal impairment (creatinine clearance below 30 ml/min). Both risedronate and calcium handling are impaired in kidney disease.
• Recurrent calcium-containing kidney stones (nephrolithiasis or nephrocalcinosis).
• Conditions producing pathological hypercalcaemia such as primary hyperparathyroidism or sarcoidosis.
• Inability to stand or sit upright for 30 minutes after the risedronate dose, because of the increased risk of oesophageal adverse events.
• Pregnancy and breastfeeding.

Warnings and Precautions

The following conditions require careful discussion with your doctor and may require additional precautions during treatment.

Oesophageal and upper gastrointestinal disorders: Risedronate can cause oesophageal irritation and, rarely, ulceration. Patients with known oesophageal disorders that delay oesophageal emptying (such as stricture or achalasia), active dysphagia, severe gastro-oesophageal reflux, gastritis, duodenitis, or active peptic ulcer disease should be evaluated before starting treatment. If symptoms of oesophageal reaction develop (painful swallowing, new or worsening heartburn, retrosternal pain), stop the risedronate tablet and contact a doctor promptly.

Calcium and vitamin D status: The calcium component of Optinate Combi meets most patients' daily supplementation needs, but vitamin D is not included in every formulation of the pack. Vitamin D sufficiency is essential both to absorb dietary calcium and to avoid treatment-emergent hypocalcaemia. Baseline 25-hydroxyvitamin D measurement is recommended, and many physicians co-prescribe 800–1000 IU of vitamin D3 daily if levels are not already adequate through diet and sunlight.

Osteonecrosis of the jaw (ONJ): ONJ is a rare but clinically significant adverse event associated with bisphosphonate use, characterised by exposed, non-healing bone in the jaw lasting more than eight weeks. The risk is much higher with intravenous high-dose bisphosphonates used in oncology than with oral bisphosphonates used for osteoporosis — the estimated incidence for oral bisphosphonate users is approximately 1 per 10,000 to 1 per 100,000 patient-years. Risk factors include invasive dental procedures, poorly fitting dentures, smoking, diabetes, corticosteroid co-therapy, and cancer-related illness. A dental examination and treatment of identified issues before starting therapy substantially reduces risk.

Atypical femoral fractures (AFF): Rare low-trauma fractures of the femoral shaft have been reported with long-term bisphosphonate use. These fractures often follow a prodrome of thigh, hip, or groin pain over weeks to months and can be bilateral. The absolute risk is very low but rises with longer treatment duration. Periodic reassessment of treatment need after 3–5 years is standard practice.

Osteonecrosis of the external auditory canal: Rare cases of osteonecrosis affecting the ear canal have been reported, mainly with long-term bisphosphonate therapy. Contact your doctor if you develop persistent ear pain, discharge, or hearing loss during treatment.

Renal function: Risedronate is cleared by the kidneys, and the calcium component can also contribute to renal stress at high doses. Baseline and periodic assessment of creatinine and estimated glomerular filtration rate (eGFR) is recommended, particularly in elderly patients or those with other risk factors for kidney disease. Severe renal impairment (CrCl < 30 ml/min) is a contraindication.

Hepatic impairment: Risedronate undergoes minimal hepatic metabolism and no specific dose adjustment is required in mild-to-moderate liver disease. Data in severe hepatic impairment are limited.

Elderly patients: No dose adjustment is required based on age alone. Elderly patients often have reduced renal function and multiple co-morbidities, so renal function should be assessed periodically.

Pregnancy and Breastfeeding

Optinate Combi is contraindicated during pregnancy and breastfeeding. Bisphosphonates are incorporated into bone matrix and can be released slowly for many years after discontinuation, so potential foetal exposure may persist. Animal studies have shown adverse effects at high doses, and human data are insufficient to exclude risk. Optinate Combi is intended for postmenopausal women; it should not be used in women of reproductive potential except under specialist supervision in very rare clinical circumstances. If pregnancy is planned or suspected during treatment, stop the medication and consult your doctor immediately.

Children and Adolescents

Optinate Combi is not recommended in children or adolescents under 18. Safety and efficacy have not been established in this population, and paediatric osteoporosis requires specialist evaluation in a tertiary setting.

Driving and Operating Machinery

Risedronate and calcium have no known clinically significant effect on the ability to drive or operate machinery. However, if you experience dizziness, severe musculoskeletal pain, or (rarely) visual disturbances during treatment, avoid driving until symptoms have resolved and you have consulted a healthcare professional.

How Does Optinate Combi Interact with Other Drugs?

Drug interactions with Optinate Combi are predominantly pharmacokinetic rather than pharmacodynamic. Because risedronate has an oral bioavailability of only about 0.63% under fasting conditions, any substance that further reduces absorption can have a significant clinical impact. The calcium sachets share the same chelation-based interaction pattern with certain antibiotics, thyroid hormone, and iron salts. Careful separation of these products in time is the main strategy to preserve efficacy.

Major Interactions That Reduce Risedronate Absorption

Products containing polyvalent cations (calcium, magnesium, aluminium, iron, zinc) bind with the bisphosphonate group of risedronate to form insoluble complexes that are not absorbed. On the day you take the risedronate tablet, avoid all such products for at least 30 minutes before and after dosing. This is also why the Optinate Combi calcium sachets are scheduled for separate days from the risedronate tablet.

Interactions Caused by the Calcium Component

The calcium sachets themselves can affect absorption of certain other medicines by the same chelation mechanism. When possible, separate the following medications from the calcium sachets by at least 2 hours.

Other Pharmacological Considerations

NSAIDs and aspirin: Non-steroidal anti-inflammatory drugs can irritate the upper gastrointestinal tract, and the combination with bisphosphonates may theoretically increase the risk of gastrointestinal adverse effects, particularly in elderly patients or those with previous peptic ulcer disease. Short-term or intermittent NSAID use is generally acceptable, but long-term concomitant use should be monitored.

Proton pump inhibitors (PPIs) and H₂-receptor antagonists: These acid-suppressing medications can reduce calcium carbonate dissolution and therefore absorption (calcium citrate is less affected, but Optinate Combi uses carbonate). In patients on long-term high-dose PPIs, physicians may opt for a different calcium salt or monitor serum calcium. There is also epidemiological evidence that long-term PPI use is independently associated with a small increase in fracture risk.

Systemic corticosteroids: Long-term corticosteroid therapy causes glucocorticoid-induced osteoporosis and is itself an indication for bisphosphonate therapy. There is no pharmacokinetic interaction between corticosteroids and risedronate; the combination is often clinically appropriate.

Cytochrome P450 interactions: Risedronate is not metabolised by CYP450 enzymes and does not induce or inhibit them. Clinically relevant metabolic interactions with drugs such as warfarin, statins, antidepressants, or antiepileptics are unlikely.

What Is the Correct Dosage of Optinate Combi?

Proper dosing and timing are central to both safety and effectiveness. Because risedronate absorption is extremely sensitive to food, beverages, and other medications, strict adherence to the weekly schedule is one of the most important factors determining treatment success. The Optinate Combi pack is designed around this principle, with clearly labelled day slots to guide the patient.

Adults — Standard Dosing

Only plain tap water should be used for taking the risedronate tablet. Mineral water (which contains calcium and magnesium), sparkling water, coffee, tea, fruit juice, and soft drinks are all unsuitable because of their mineral or caloric content. After the 30-minute waiting period, you can resume your normal morning routine, including breakfast and other medications.

Vitamin D supplementation of approximately 800–1000 IU per day is recommended alongside Optinate Combi in most clinical protocols, unless baseline 25-hydroxyvitamin D levels are already adequate and sun exposure is sufficient. Some Optinate Combi products in certain markets may include a separate vitamin D component; always check the specific product leaflet.

Treatment Duration

Optimal duration of oral bisphosphonate therapy remains an area of active clinical debate. Major guidelines from NICE, the National Osteoporosis Foundation (NOF), the American Association of Clinical Endocrinologists (AACE), and the European Society for Clinical and Economic Aspects of Osteoporosis (ESCEO) recommend reassessing treatment need after 3–5 years. Patients at low fracture risk after initial therapy may be candidates for a “drug holiday” from the bisphosphonate (with continued calcium and vitamin D), while those at continued high risk typically remain on therapy. Decisions should be individualised based on fracture history, BMD, and comorbidities.

Missed Dose

Missed risedronate tablet: If you forget to take the weekly tablet on your usual day, take it on the morning of the following day following the same fasted procedure. Then return to your usual scheduled day in the next week. Do not take two risedronate tablets on the same day. If you only remember close to the next scheduled dose, skip the missed dose entirely and continue with the normal weekly schedule.

Missed calcium sachet: If you miss a daily sachet, take it as soon as you remember on the same day. Do not double up the next day. If you miss several sachets in a row, just resume the normal daily intake — do not attempt to “catch up” with multiple sachets.

Overdose

If You Stop Taking Optinate Combi

Bisphosphonates have a very long skeletal half-life because they are incorporated into the bone matrix, so the protective effect of risedronate does not disappear abruptly when treatment is stopped. Nevertheless, bone mineral density may gradually decrease and fracture risk may rise again, especially in patients with severe osteoporosis. Do not stop Optinate Combi on your own; any decision to pause, switch, or discontinue should be made in consultation with your doctor, ideally after a reassessment of fracture risk.

What Are the Side Effects of Optinate Combi?

Like all medications, Optinate Combi can cause side effects, although not everyone will experience them. Because the regimen combines a bisphosphonate and a calcium supplement, the possible side-effect profile reflects both components. Most adverse effects are mild and transient, but a small proportion require medical attention.

Side Effects by Frequency

Adverse effects are grouped below using the standard MedDRA frequency categories used in European prescribing information.

Atypical Femoral Fractures

Atypical (non-traumatic) fractures of the proximal femoral shaft have been reported in patients on long-term bisphosphonate therapy. They are typically preceded by weeks to months of persistent thigh, hip, or groin pain and often occur bilaterally. Estimated incidence with oral bisphosphonates is around 3–5 per 10,000 patient-years, which must be weighed against the substantial fracture prevention benefit in patients with active osteoporosis. Any new thigh, hip, or groin pain during long-term treatment warrants clinical evaluation and often radiographic imaging of the entire femur.

Osteonecrosis of the Jaw

Osteonecrosis of the jaw is a rare complication of bisphosphonate therapy, typically triggered by invasive dental procedures in patients with underlying risk factors such as smoking, diabetes, corticosteroid use, or oral infection. With oral bisphosphonates used for osteoporosis, the estimated incidence is approximately 1 per 10,000 to 1 per 100,000 patient-years — far lower than with intravenous bisphosphonates used in oncology. Good oral hygiene, regular dental examinations, and completion of elective dental work before starting therapy substantially reduces risk.

Hypercalcaemia and Calcium-Related Events

The daily calcium component of Optinate Combi generally delivers a physiological dose appropriate for most postmenopausal women, but certain patient groups are at higher risk of hypercalcaemia or hypercalciuria: those on thiazide diuretics, those with hyperparathyroidism, those with sarcoidosis, and those with pre-existing renal impairment. Periodic laboratory monitoring is recommended in these groups. Symptoms of significant hypercalcaemia include nausea, vomiting, abdominal pain, excessive thirst and urination, confusion, and cardiac arrhythmia — any of these warrant prompt medical evaluation.

Reassurance Context

Most people who take Optinate Combi tolerate it well. In large randomised trials of oral risedronate, discontinuation rates due to adverse events have been broadly similar to placebo in many studies, and mild gastrointestinal symptoms — the most common reason for discontinuation — tend to improve with continued use and correct administration technique. The structured day-by-day dosing schedule of Optinate Combi is specifically designed to maximise adherence and therefore long-term benefit.

How Should You Store Optinate Combi?

Proper storage preserves both the chemical stability of risedronate and the physical integrity of the calcium granules. Optinate Combi should be stored at controlled room temperature, generally below 25°C (77°F), in its original packaging. The risedronate tablets come in a blister pack that protects them from moisture and light, and the calcium sachets are individually foil-sealed to maintain the granules' dry state. Avoid transferring either component to pill organisers for long periods in advance, as their original packaging provides essential protection. Do not store the medication in bathrooms or kitchens, where humidity and temperature fluctuate significantly.

Keep Optinate Combi out of the sight and reach of children at all times. Accidental ingestion of a risedronate tablet can cause significant oesophageal irritation and, at high doses, symptomatic hypocalcaemia. Accidental ingestion of multiple calcium sachets can cause hypercalcaemia. If accidental ingestion occurs, follow the overdose guidance in the dosage section and contact emergency services or a poison control centre immediately.

Always check the expiry date before use. The date printed on the outer carton and on the blister pack or sachet foil, usually after “EXP”, refers to the last day of the month printed. Do not use Optinate Combi after this date; chemical stability and therefore effectiveness may be compromised. Discoloured, crumbling, or damp granules should also not be used even if the expiry date has not yet passed — return the product to your pharmacy.

Do not dispose of medication via household waste or by flushing it down the toilet. Return any unused or expired tablets and sachets to your local pharmacy for proper pharmaceutical waste disposal. These measures protect the environment and prevent accidental exposure to others.

What Does Optinate Combi Contain?

Active Ingredients

Risedronate tablet (1 per pack, taken on day 1 of each week):

• Risedronate sodium 35 mg, equivalent to approximately 32.5 mg of risedronic acid — a pyridinyl nitrogen-containing bisphosphonate that selectively suppresses osteoclast-mediated bone resorption.

Calcium sachet (6 per pack, taken on days 2–7 of each week):

• Calcium carbonate approximately 2500 mg, equivalent to 1000 mg of elemental calcium per sachet — providing the daily calcium intake required to support bone mineralisation and prevent treatment-emergent hypocalcaemia.

Inactive Ingredients (Excipients)

The complete list of excipients varies slightly by manufacturer and jurisdiction, but typically includes the following.

Risedronate tablet core:

• Microcrystalline cellulose — binder and filler.
• Crospovidone — disintegrant that enables rapid tablet breakdown in the stomach.
• Magnesium stearate — lubricant used during tablet compression.
• Colloidal anhydrous silica — glidant that improves powder flow during manufacturing.
• Lactose monohydrate — filler (in some formulations).

Risedronate film coating:

• Hypromellose — film-former that aids swallowing.
• Macrogol / polyethylene glycol — plasticiser.
• Titanium dioxide (E171) — white colouring pigment.
• Iron oxide pigments (E172) — may contribute to tablet colour depending on the product.

Calcium sachet granules:

• Aspartame or sucralose — sweetener (aspartame-containing products carry a phenylalanine warning for people with phenylketonuria).
• Citric acid — effervescent acid component (in effervescent formulations).
• Sodium bicarbonate — effervescent base component (sodium content relevant for low-sodium diets).
• Orange, lemon, or other natural flavourings.
• Povidone — granulation binder.
• Sorbitol — bulking agent (some products may contain small amounts).

Appearance and Packaging

Optinate Combi is supplied in a monthly carton designed to match the weekly dosing schedule. A typical pack contains 4 risedronate 35 mg film-coated tablets in a blister with clearly labelled day-of-week positions, and 24 individually sealed calcium 1000 mg sachets arranged to support the remaining 6 days of each week. The outer packaging uses a calendar-style layout to help patients track their weekly progress. Not all pack sizes may be marketed in every country.

References

This article is based on the following peer-reviewed sources and international medical guidelines:

1. Wells GA, Cranney A, Peterson J, et al. Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database of Systematic Reviews. 2008;(1):CD004523. doi:10.1002/14651858.CD004523.pub3
2. Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. JAMA. 1999;282(14):1344-1352. doi:10.1001/jama.282.14.1344
3. McClung MR, Geusens P, Miller PD, et al. Effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med. 2001;344(5):333-340. doi:10.1056/NEJM200102013440503
4. European Medicines Agency (EMA). Risedronate sodium — Summary of Product Characteristics (SmPC). EMA, 2024.
5. U.S. Food and Drug Administration (FDA). Actonel (risedronate sodium) Prescribing Information. FDA, updated 2023.
6. National Institute for Health and Care Excellence (NICE). Bisphosphonates for treating osteoporosis. NICE Technology Appraisal Guidance [TA464], updated 2023.
7. World Health Organization. WHO Model List of Essential Medicines — 23rd edition. WHO, 2023.
8. Tang BMP, Eslick GD, Nowson C, Smith C, Bensoussan A. Use of calcium or calcium in combination with vitamin D supplementation to prevent fractures and bone loss in people aged 50 years and older: a meta-analysis. Lancet. 2007;370(9588):657-666.
9. Adler RA, El-Hajj Fuleihan G, Bauer DC, et al. Managing osteoporosis in patients on long-term bisphosphonate treatment: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2016;31(1):16-35.
10. Camacho PM, Petak SM, Binkley N, et al. American Association of Clinical Endocrinologists/American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis — 2020 Update. Endocr Pract. 2020;26(Suppl 1):1-46.
11. Khan AA, Morrison A, Hanley DA, et al. Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. J Bone Miner Res. 2015;30(1):3-23.
12. Shane E, Burr D, Abrahamsen B, et al. Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2014;29(1):1-23.
13. Kanis JA, Cooper C, Rizzoli R, Reginster JY; ESCEO. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int. 2019;30(1):3-44.
14. British National Formulary (BNF). Risedronate Sodium; Calcium Carbonate. Joint Formulary Committee, updated 2025.
15. Institute of Medicine (US) Committee to Review Dietary Reference Intakes for Vitamin D and Calcium. Dietary Reference Intakes for Calcium and Vitamin D. Washington, DC: National Academies Press; 2011.

Editorial Team

This article has been researched, written, and medically reviewed by the iMedic Medical Editorial Team, comprising licensed specialist physicians in endocrinology, clinical pharmacology, and internal medicine. All recommendations reflect current international guidelines and peer-reviewed clinical evidence.